Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. reports news on its medical supplies business, centered on insulin delivery products and diabetes-care devices. The company sells pen needles, syringes and safety devices through wholesalers, distributors and institutional channels, and it has described a transition from insulin delivery toward a broader medical supplies platform.
Recurring updates include quarterly operating and financial results, cash dividend declarations, conference participation, board leadership changes, operational updates, capital-structure matters, material agreements, and regulatory or clinical disclosures tied to its device portfolio and manufacturing activities.
Embecta Corp. reported solid financial results for Q2 and the first half of fiscal year 2024, showcasing resilience in base business and strong operational execution. The company saw revenue growth, increased gross profit and margin, and positive adjusted net income. Strategic highlights include strengthening the base business and investing for growth with FDA review progress on insulin delivery systems.
Embecta Corp. (EMBC) announced a quarterly cash dividend of $0.15 per share for stockholders, payable on June 14, 2024. The dividend will be given to shareholders of record as of May 28, 2024.
Embecta Corp. (
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.